24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
Fax: (361)578-5500
Regular Hours: M-Fri 8am - 5pm
Every 3rd Thurs of the Month - Extended Hours Until 7 pm

Medical Disorders
Resources
Basic InformationLookupsLatest News
State Lotteries Didn't Help Boost Vaccination RatesFDA Panel Recommends Approval of Johnson & Johnson Booster ShotHeart Defibs in Schools Are Saving Staff Lives: StudyHorseback Riding Carries Big Risk for Serious Injury: StudyTwo-Thirds of Parents of Kids Ages 5-11 Plan to Get Them Vaccinated Against COVID: PollAnother Study Finds Pfizer, Moderna Shots Effective Against COVID VariantsLyme Disease Often Spotted at Later Stage in Black PatientsFDA Panel Supports Moderna Booster Shot for Older Adults, People at High RiskIs a Really Bad Flu Season on the Way?Climate Change Could Bring Rising Obesity RatesKids Can Carry High, Infectious Levels of COVID CoronavirusMore Than Half of COVID-19 Survivors Will Get 'Long COVID'One-Third of Americans With Arthritis Get No ExerciseDeath Threats, Trolling Common for Scientists Who Speak to Media About COVIDAHA News: The Differences and Similarities Between the Flu and COVID-19FDA Questions Strength of Johnson & Johnson's Booster Shot DataHelmets Can Saves Lives in ATV, Dirt Bike CrashesCancer Care Costs U.S. $156 Billion Per Year; Drugs a Major FactorFDA Expert Panel to Weigh Approval of Moderna, Johnson & Johnson Booster ShotsAnti-Nausea Drug May Boost Survival for Some Cancer PatientsExpert Panel Backs Off Recommendation for Aspirin to Prevent Heart TroubleClot-Busting Drugs Safe in Stroke Patients When Brain Aneurysm Hasn't RupturedAccess to Top Drugs Makes the Difference for Black Lung Cancer PatientsRisk of COVID from Grocery Store Surfaces Very Low: Study60% of Americans Will Delay or Skip Flu Shot This Year: SurveyGolf Cart Injuries Keep Rising Among U.S. KidsMerck Asks FDA to Approve First COVID Antiviral PillWhen COVID Triggers Loss of Smell, Younger Patients Recover It SoonerSurgery Often a Gateway to Opioid Abuse, Study ConfirmsSymptomatic COVID Could Bring on Emergency Delivery in Pregnant WomenWhy Skin Cancer Checks Are Even More Important for Hispanic PeopleSocial Distancing Kept Kids From Getting Flu, RSVAir and Noise Pollution May Make You Vulnerable to Heart FailureCDC Urges Flu Shots as Survey Shows Half of Americans Don't Plan on ItPfizer Seeks FDA Emergency Approval for COVID Vaccine in Younger KidsCould an App Help Kids With Severe Ear Condition Avoid Surgery?1 in 7 Cancer Patients Worldwide Missed a Surgery Due to PandemicWestern Wildfires Are Making Easterners Sick: U.S. StudyStudies Show Power of Pfizer Vaccine Starts to Wane After Two MonthsJapanese Scientists Discover New Disease Carried by TicksOver 140,000 U.S. Children Have Lost a Caregiver to COVID-19Could Too Little Iron Boost Your Risk for Heart Disease?COVID Hospitalizations Are Rising Among Unvaccinated Pregnant WomenAs You Age, Your 'Microbiome' ChangesWHO Approves First Malaria Vaccine, a Lifesaver for Children WorldwideU.S. to Buy $1 Billion Worth of Rapid COVID Tests1 in 10 People Have Gastro Issues After a MealNearly 200,000 COVID Home Tests Recalled Over False PositivesBig Rise in Injuries From E-Scooters, HoverboardsStatins: Good for the Heart, Maybe Not So Good for Diabetes
Questions and AnswersLinks
Related Topics

Diabetes

Nearly 200,000 COVID Home Tests Recalled Over False Positives

HealthDay News
by Robert Preidt and Robin Foster
Updated: Oct 6th 2021

new article illustration

WEDNESDAY, Oct. 6, 2021 (HealthDay News) -- Almost 200,000 Ellume COVID-19 home testing kits have been recalled because they may be more likely to give a false positive result.

The problem with the rapid antigen tests was identified in mid-September and caused by variations in the quality of one of the raw materials used in the products, Ellume CEO Dr. Sean Parsons told The New York Times.

The Ellume test kits received emergency use authorization from the U.S. Food and Drug Administration last December, and the Australian company had already shipped about 3.5 million of the test kits to this country.

About 427,000 of those kits were affected by the problem, and about half have already been used, returning about 42,000 positive results, Parsons told the Times.

He said it would be difficult to determine how many of those positive results may have been incorrect, but said the rate could be as high as one quarter.

The issue with the recalled test kits doesn't affect the reliability of negative results, according to the company.

Ellume's test is designed to detect pieces of the virus in the nose. After swabbing the nostrils, the swab is inserted into a dropper of fluid, and the fluid is then added to a Bluetooth-connected analyzer. Results arrive via a smart phone app in 15 minutes.

The company said it has asked retailers to stop selling the recalled kits and has notified consumers about the issue.

Consumers should go to the Ellume website to see if their home test kit is included in the recall and to get instructions on what to do if it is, the company said.

To arrange a replacement, consumers can call Ellume at 1-888-807-1501, 9 a.m. to 5 p.m. ET, Monday through Friday.

People who try to use one of the affected test kits will be notified in the app that the test has been recalled, Parsons explained. "It really won't be possible to use any of those tests now," he added.

He noted that the company had put "extra controls" in place to prevent the same problem from happening again in the future.

"I'm very sorry that this has happened," Parsons told the Times. "We're all about chasing accuracy, and to have these false positives is disappointing."

The recall comes as demand for at-home testing has soared, and consumers have complained that test kits are hard to find, the Times reported.

On Monday, a new at-home antigen test from ACON Laboratories was approved for emergency use by the FDA.

That approval "is expected to double rapid at-home testing capacity in the U.S. over the next several weeks," Dr. Jeffrey Shuren, who directs the FDA's Center for Devices and Radiological Health, said in a statement. "By year's end, the manufacturer plans to produce more than 100 million tests per month, and this number will rise to 200 million per month by February 2022."

"Since March 2020, the FDA has authorized more than 400 COVID-19 tests and sample collection devices, including authorizations for rapid, OTC at-home tests," Shuren added. "The FDA considers at-home COVID-19 diagnostic tests to be a high priority and we have continued to prioritize their review given their public health importance."

More information

Visit the U.S. Centers for Disease Control and Prevention for more on COVID testing.


SOURCE: The New York Times; Oct. 5, 2021 statement, U.S. Food and Drug Administration